Introduction of New Dengue Virus Lineages of Multiple Serotypes after COVID-19 Pandemic, Nicaragua, 2022
Cristhiam Cerpas, Gerald Vásquez, Hanny Moreira, Jose G. Juarez, Josefina Coloma, Eva Harris
1 , Shannon N. Bennett
1, and Ángel Balmaseda
1
Author affiliations: Sustainable Sciences Institute, Managua, Nicaragua (C. Cerpas, G. Vásquez, H. Moreira, J.G. Juarez, Á. Balmaseda); Laboratorio Nacional de Virologia, Centro Nacional de Diagnóstico y Referencia Ministerio de Salud, Managua (C. Cerpas, Á. Balmaseda); Division of Infectious Diseases and Vaccinology, School of Public Health, University of California Berkeley, Berkeley, California, USA (J. Coloma, E. Harris); California Academy of Sciences, San Francisco, California, USA (S.N. Bennett)
Main Article
Figure 1
Figure 1. DENV serotypes 1–4 circulation in Nicaragua during 1998–2022. Data on dengue cases with serotype information available were obtained from the Nicaraguan Dengue Surveillance Program; many more cases were confirmed via serology that are not included here because the serotype is unknown. A) Total dengue cases by serotype and year. B) Percentage of circulating dengue cases by serotype and year. C) Case count of each serotype identified by real-time reverse transcription PCR over time during January–December 2022. DENV, dengue virus.
Main Article
Page created: May 02, 2024
Page updated: May 22, 2024
Page reviewed: May 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.